Trials / Completed
CompletedNCT04124965
A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
A Randomized, Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rozanolixizumab | Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2. |
Timeline
- Start date
- 2019-10-29
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2019-10-14
- Last updated
- 2023-09-05
- Results posted
- 2023-08-21
Locations
43 sites across 12 countries: United States, Canada, Czechia, Denmark, France, Germany, Italy, Japan, Poland, Russia, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04124965. Inclusion in this directory is not an endorsement.